Gateway Investment Advisers LLC Acquires New Shares in United Therapeutics Co. (NASDAQ:UTHR)

Gateway Investment Advisers LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 958 shares of the biotechnology company’s stock, valued at approximately $220,000.

Several other institutional investors also recently modified their holdings of UTHR. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the first quarter valued at $32,000. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $43,000. Blue Trust Inc. boosted its position in shares of United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of United Therapeutics by 31.2% during the fourth quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 138 shares during the last quarter. Finally, CWM LLC boosted its position in United Therapeutics by 45.7% in the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 210 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.0 %

Shares of UTHR opened at $318.95 on Thursday. The business’s 50 day moving average is $271.56 and its 200 day moving average is $243.07. The company has a market capitalization of $14.15 billion, a PE ratio of 15.08, a price-to-earnings-growth ratio of 4.77 and a beta of 0.49. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $321.80. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the company earned $4.86 EPS. Research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $8,530,302.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $233.27, for a total value of $3,499,050.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,325.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total value of $1,394,220.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,530,302.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 122,744 shares of company stock valued at $31,286,630. 12.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on UTHR. The Goldman Sachs Group raised their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company raised their target price on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Oppenheimer raised their target price on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, JPMorgan Chase & Co. raised their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $312.22.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.